To identify patients with intermediate risk prostate cancer (IRPC) benefiting from de-escalation of androgen deprivation therapy (ADT) and/or dose escalated radiotherapy (DERT), we performed a secondary analysis of a phase III trial by measuring biochemical failure (BF), distant metastases (DM), prostate cancer specific mortality (PCSM), overall survival (OS) and distant metastases-free survival (DMFS) rates according to prognostic intermediate risk factors (IRF).